FDB's Patient-Specific Medication Guidance Cuts Pharmacy Alerts by 70%

Event summary

  • FDB's patient-specific medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting.
  • The approach consolidates multiple medication safety alerts into a single, actionable alert based on the patient's most clinically relevant risk.
  • Pharmacists' acceptance of recommended next-best actions exceeded 75%, with higher satisfaction and more dedicated time for patient interaction.
  • FDB delivers this approach through FDB Navigo™, a web-based API solution that replaces siloed, severity-based alerts with consolidated, risk-based guidance.
  • The research will be presented at the 2026 AMIA Amplify Informatics Conference on May 20, 2026.

The big picture

FDB's research highlights a critical shift in pharmacy workflow optimization, addressing the growing issue of alert fatigue. As community pharmacists take on more responsibilities, such as vaccinations and medication therapy management, reducing cognitive burden becomes increasingly important. This innovation aligns with broader industry trends towards more patient-centered care and efficient, actionable clinical decision support systems. FDB's solution could set a new standard for medication guidance in community pharmacies.

What we're watching

Adoption Pace
How quickly community pharmacies will adopt FDB Navigo given its proven alert reduction capabilities.
Clinical Impact
Whether the reduction in alert volume will sustain or improve clinical outcomes over time.
Market Differentiation
The extent to which FDB's patient-specific approach will differentiate it from competitors in the clinical decision support space.